MedTrace Logo

Application of UCPCR as a Testing Tool for Identification of MODY Patients in the UAE

NCT03607604 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 778

Last updated 2020-08-19

No results posted yet for this study

Summary

The study aims to investigate the validity of 2 hour post-prandial UCPCR test in paediatric and adult patients with diabetes duration greater than 2 and 5 years, respectively, for the purposes of distinguishing between patients with type 1 diabetes and MODY in the UAE population.

Conditions

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Maturity-onset Diabetes of the Young

Interventions

GENETIC

Next generation sequencing (NGS)

Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.

Sponsors & Collaborators

  • Imperial College London Diabetes Centre

    lead OTHER

Principal Investigators

  • Nader Lessan, MBBS FRCP MD · Imperial College London Diabetes Centre

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03607604 on ClinicalTrials.gov